Abstract 3668
Background
Colorectal cancer is the third most common cancer and second leading cause of cancer mortality in Australia. In patients with metastatic disease who have progressed after two lines of therapies, survival is 4-6 months with best supportive care, and 6-8 months with newer agents. This retrospective analysis aims to explore real-world treatment landscape of metastatic colorectal cancer in the third-line setting.
Methods
We analysed the TRACC (Treatment of Recurrent and Advanced Colorectal Cancer) registry database from 2009 onwards. Patients treated with palliative intent who have progressed after two lines of therapies were included. One treatment line is defined as any combination of systemic therapy given until progression. Patient demographics, third line choices and survival outcomes were examined.
Results
A total of 2831 patients had metastatic colorectal cancer, and of these, 23% (642 patients) met study criteria. 48% (306 patients) of study population proceeded to receive third line therapy. A large proportion of patients had received doublet chemotherapy in both first and second lines. Median age was 62 years and ECOG at the start of third line was 1-2 (75%). A fluoropyrimidine-based doublet with oxaliplatin or irinotecan was the most common treatment choice in 42%. Other treatments included mono-chemotherapy +/- biological agent (23%), EGFR inhibitor alone (22%), EGFR inhibitor with doublet chemotherapy (6%), trifluridine/tipiracil (4%), regorafenib (2%), immunotherapy (<1%), clinical trials (1%), others (<1%). Median duration on third-line treatment was 2.4 months (0.07 – 40). Median overall survival (OS) was 8.7 months (0.4 – 58).
Conclusions
In a real-world Australian population, 11% of all patients diagnosed with metastatic disease received third line treatment, with commonest regimens being doublet chemotherapy. This treatment landscape may change with the approval of new drugs. Overall survival in these patients is comparable to third line trials on these agents. Analyses are underway to further characterise the breakdown of treatment regimens in all three lines in these patients, and assess survival with rechallenge regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract